update: Provectus Biopharmaceuticals' Protocol for Phase 2 Study of Mechanism of Action of PH-10 on Immunologic Makers of Psoriasis

By: via Benzinga
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.pvct.com), a development-stage oncology and dermatology biopharmaceutical ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.